BACKGROUND: We compared Kaposi sarcoma (KS) risk in adults who started antiretroviral therapy (ART) across the Asia-Pacific, South Africa, Europe, Latin, and North America. METHODS: We included cohort data of human immunodeficiency virus (HIV)-positive adults who started ART after 1995 within the framework of 2 large collaborations of observational HIV cohorts. We present incidence rates and adjusted hazard ratios (aHRs). RESULTS: We included 208140 patients from 57 countries. Over a period of 1066572 person-years, 2046 KS cases were diagnosed. KS incidence rates per 100000 person-years were 52 in the Asia-Pacific and ranged between 180 and 280 in the other regions. KS risk was 5 times higher in South African women (aHR, 4.56; 95% confidence intervals [CI], 2.73-7.62) than in their European counterparts, and 2 times higher in South African men (2.21; 1.34-3.63). In Europe, Latin, and North America KS risk was 6 times higher in men who have sex with men (aHR, 5.95; 95% CI, 5.09-6.96) than in women. Comparing patients with current CD4 cell counts ≥700 cells/µL with those whose counts were <50 cells/µL, the KS risk was halved in South Africa (aHR, 0.53; 95% CI, .17-1.63) but reduced by ≥95% in other regions. CONCLUSIONS: Despite important ART-related declines in KS incidence, men and women in South Africa and men who have sex with men remain at increased KS risk, likely due to high human herpesvirus 8 coinfection rates. Early ART initiation and maintenance of high CD4 cell counts are essential to further reducing KS incidence worldwide, but additional measures might be needed, especially in Southern Africa.
BACKGROUND: We compared Kaposi sarcoma (KS) risk in adults who started antiretroviral therapy (ART) across the Asia-Pacific, South Africa, Europe, Latin, and North America. METHODS: We included cohort data of human immunodeficiency virus (HIV)-positive adults who started ART after 1995 within the framework of 2 large collaborations of observational HIV cohorts. We present incidence rates and adjusted hazard ratios (aHRs). RESULTS: We included 208140 patients from 57 countries. Over a period of 1066572 person-years, 2046 KS cases were diagnosed. KS incidence rates per 100000 person-years were 52 in the Asia-Pacific and ranged between 180 and 280 in the other regions. KS risk was 5 times higher in South African women (aHR, 4.56; 95% confidence intervals [CI], 2.73-7.62) than in their European counterparts, and 2 times higher in South African men (2.21; 1.34-3.63). In Europe, Latin, and North America KS risk was 6 times higher in men who have sex with men (aHR, 5.95; 95% CI, 5.09-6.96) than in women. Comparing patients with current CD4 cell counts ≥700 cells/µL with those whose counts were <50 cells/µL, the KS risk was halved in South Africa (aHR, 0.53; 95% CI, .17-1.63) but reduced by ≥95% in other regions. CONCLUSIONS: Despite important ART-related declines in KS incidence, men and women in South Africa and men who have sex with men remain at increased KS risk, likely due to high human herpesvirus 8 coinfection rates. Early ART initiation and maintenance of high CD4 cell counts are essential to further reducing KS incidence worldwide, but additional measures might be needed, especially in Southern Africa.
Authors: Stephen J Gange; Mari M Kitahata; Michael S Saag; David R Bangsberg; Ronald J Bosch; John T Brooks; Liviana Calzavara; Steven G Deeks; Joseph J Eron; Kelly A Gebo; M John Gill; David W Haas; Robert S Hogg; Michael A Horberg; Lisa P Jacobson; Amy C Justice; Gregory D Kirk; Marina B Klein; Jeffrey N Martin; Rosemary G McKaig; Benigno Rodriguez; Sean B Rourke; Timothy R Sterling; Aimee M Freeman; Richard D Moore Journal: Int J Epidemiol Date: 2007-01-08 Impact factor: 7.196
Authors: Catherine C McGowan; Pedro Cahn; Eduardo Gotuzzo; Denis Padgett; Jean W Pape; Marcelo Wolff; Mauro Schechter; Daniel R Masys Journal: Int J Epidemiol Date: 2007-09-10 Impact factor: 7.196
Authors: Emilio Letang; Jose M Almeida; Jose M Miró; Edgar Ayala; Irene E White; Carla Carrilho; Rui Bastos; Tacilta Nhampossa; Clara Menéndez; Thomas B Campbell; Pedro L Alonso; Denise Naniche Journal: J Acquir Immune Defic Syndr Date: 2010-04 Impact factor: 3.731
Authors: Aggrey Semeere; Megan Wenger; Naftali Busakhala; Nathan Buziba; Mwebesa Bwana; Winnie Muyindike; Erin Amerson; Toby Maurer; Timothy McCalmont; Philip LeBoit; Beverly Musick; Constantin Yiannoutsos; Robert Lukande; Barbara Castelnuovo; Miriam Laker-Oketta; Andrew Kambugu; David Glidden; Kara Wools-Kaloustian; Jeffrey Martin Journal: Cancer Med Date: 2016-01-28 Impact factor: 4.452
Authors: Ramya Ramaswami; Mark N Polizzotto; Kathryn Lurain; Kathleen M Wyvill; Anaida Widell; Jomy George; Priscila Goncalves; Seth M Steinberg; Denise Whitby; Thomas S Uldrick; Robert Yarchoan Journal: Clin Cancer Res Date: 2022-03-01 Impact factor: 13.801
Authors: Susan E Krown; Carlee B Moser; Patrick MacPhail; Roy M Matining; Catherine Godfrey; Stephanie R Caruso; Mina C Hosseinipour; Wadzanai Samaneka; Mulinda Nyirenda; Naftali W Busakhala; Fred M Okuku; Josphat Kosgei; Brenda Hoagland; Noluthando Mwelase; Vincent O Oliver; Henriette Burger; Rosie Mngqibisa; Mostafa Nokta; Thomas B Campbell; Margaret Z Borok Journal: Lancet Date: 2020-03-05 Impact factor: 79.321
Authors: Elaine Chang; Srikar R Mapakshi; Pamela Mbang; Nader Kim El-Mallawany; Jennifer R Kramer; Donna L White; Elizabeth Y Chiao Journal: J Acquir Immune Defic Syndr Date: 2018-10-01 Impact factor: 3.771
Authors: Valeria I Fink; Cathy A Jenkins; Jessica L Castilho; Anna K Person; Bryan E Shepherd; Beatriz Grinsztejn; Juliana Netto; Brenda Crabtree-Ramirez; Claudia P Cortés; Denis Padgett; Karu Jayathilake; Catherine McGowan; Pedro Cahn Journal: Infect Agent Cancer Date: 2018-05-08 Impact factor: 2.965